Bisphosphonates for osteoporosis not associated with reduced breast cancer risk, study suggests

An analysis of data from two randomized clinical trials finds that 3-4 years of treatment with bisphosphonates to improve bone density is not linked to reduced risk of invasive postmenopausal breast cancer. Some studies have suggested that bisphosphonates, which are commonly used to treat osteoporosis, may have antitumor and antimetastatic properties. Some observational studies have suggested bisphosphonates may protect women from breast cancer.

Read the whole article on Science Daily

More from Science Daily